Oliver Ottmann, MD, FRCPath, University of Cardiff, Cardiff, UK, discusses how molecular profiling and genome sequencing will act as a turning point for deciding treatment options for patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This is due to prevalent genetic aberrations in these diseases. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJhemOnc).